Viemed Healthcare: Download the Investor Relations presentation


Disclaimer and other important information

This presentation (the “Presentation”) on Viemed Healthcare, Inc. (“Viemed”) is dated August 2022. It is in summary form and does not purport to be complete. The data contained in this document comes from various internal and external sources. This presentation is not intended to be advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. No representations or warranties, express or implied, are made or given by or on behalf of Viemed or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information. or opinions contained in this presentation and no responsibility or liability is accepted by any person for such information or opinions. Viemed neither undertakes nor agrees to update this presentation or to correct any inaccuracies or omissions in this presentation which may become apparent. No one has been authorized to give any information or make any statement other than that contained in this presentation and, if given and/or made, such information or statement should not be deemed to have been so authorized. The content of this presentation should not be construed as legal, financial or tax advice.

Forward-looking statements

Certain statements contained in this presentation may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 or “forward-looking information” as that term is defined in applicable Canadian securities laws (collectively, ” statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “anticipates”, “expects”, “is planned”, “budget”, “potential” , “planned”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes” or “plans”, or negative forms thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “could”, “could”, “would”, “could” or “will be taken”, “will occur” or “will be carried out” or the negative form of these terms or comparable terminology. All statements other than statements of historical fact, including those that express or imply discussions of expectations, beliefs, plans, goals, assumptions, or future events or performance, including projected U.S. DME expenditures and Viemed’s technology and marketing initiatives and objectives for the next 24 months, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. These statements reflect Viemed’s current beliefs and intentions regarding future events, as well as current information available to Viemed, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by these forward-looking statements to differ from those described herein if one or more of these risks or uncertainties materializes. These factors include, but are not limited to: general business, trade and economic conditions in the regions in which Viemed operates; Viemed may be subject to significant capital requirements and operational risks; Viemed’s ability to implement business strategies and seize business opportunities; the volatility of the market price of Viemed common stock; Viemed’s new business model; the risk that the impact of the COVID-19 pandemic and actions taken by governmental authorities, individuals and businesses in response to the pandemic on Viemed’s business, financial condition and results of operations, including based on Viemed’s patients, revenues, employees, and equipment and supplies; the clinical application of treatments that demonstrate positive results in a study may not be replicated positively or that such test results may not be predictive of actual treatment outcomes or may not lead to adoption of such treatments by providers ; the state of capital markets; the availability of funds and resources to continue operations; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private paying entities; reliance on a few payers; possible discoveries of new drugs; dependence on major suppliers and the recall of certain Royal Philips BiPAP and CPAP devices and mechanical ventilators that Viemed distributes and sells; permitting and licensing in a highly regulated business; competition; low profit market segments; disruptions or attacks (including cyberattacks) on Viemed’s information technology, Internet, network access, or other voice or data communication systems or services; the evolution of various types of fraud or other criminal behavior to which Viemed is exposed; non-compliance by third parties with their obligations; difficulty integrating newly acquired businesses; the impact of new laws and regulations, changes or enforcement thereof; the generally difficult legal and regulatory environment; increased competition; changes in exchange rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes in accounting standards, policies and methods used by Viemed; Viemed’s status as an emerging growth company; and the occurrence of catastrophic natural and unnatural events or epidemics or health issues, such as the COVID-19 pandemic, and claims resulting from such events or issues; and the risk factors discussed or referred to in Viemed’s filings with the United States Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec .gov, including Viemed’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with securities regulators in certain provinces of Canada available at If any factor affects Viemed in an unexpected way, or if the assumptions underlying the forward-looking statements prove incorrect, the actual results or events could differ materially from the results or events predicted. These forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further, Viemed assumes no responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation, and Viemed undertakes no obligation to publicly update or revise any forward-looking statements, except as required by applicable law.

Market and industry data

Industry and market data used in this presentation is unaudited and was obtained from industry publications and third-party sources as well as research reports prepared for other purposes. Viemed has not independently verified the data obtained from these sources and cannot assure you of the accuracy or completeness of the data. These data are subject to change and cannot always be verified with absolute certainty due to limitations in the availability and reliability of the raw data, the voluntary nature of the data collection process, and other limitations and uncertainties inherent in any statistical survey of market or industry data. You are cautioned not to overemphasize this industry and market data.

Non-GAAP and Other Financial Information

This presentation includes references to financial measures that are calculated and presented based on methodologies other than those in accordance with generally accepted accounting principles in the United States of America (“GAAP”), including revenue measures. net and adjusted EBITDA. A reconciliation of certain of these non-GAAP financial measures to the nearest GAAP measure can be found in the appendix to this presentation.

No offer or solicitation

This presentation does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of Viemed’s securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration. or qualification under the securities laws of such jurisdiction. Recipients of this presentation who are considering acquiring Viemed securities are referred to all of the information made public concerning Viemed. The information is subject to material updates, revisions and other changes, and is fully qualified by reference to information made publicly available by Viemed.

Comments are closed.